⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9140299 | 0.84 | — | — | |
| SCHEMBL11956609 | 0.81 | ALOX5 (0.30) | — | |
| SCHEMBL13333805 | 0.80 | ALDH1A1 (0.36) | — | |
| SCHEMBL516008 | 0.80 | ALDH1A1 (0.36) | — | |
| SCHEMBL515788 | 0.78 | ALDH1A1 (0.34) | — | |
| SCHEMBL1373549 | 0.78 | ALDH1A1 (0.34) | — | |
| SCHEMBL9449773 | 0.78 | ALDH1A1 (0.34) | — | |
| SCHEMBL17277743 | 0.75 | NEK2 (0.31) | — | |
| SCHEMBL4409815 | 0.74 | ALDH1A1 (0.34) | — | |
| SCHEMBL12087982 | 0.72 | HTR2A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-3551634-B1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | disclosed |
| EP-3551634-B1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | disclosed |
| US-10793580-B2 | Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2020-10-06 | — | — | US | disclosed |
| US-10793580-B2 | Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2020-10-06 | — | — | US | disclosed |
| US-20190330223-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2019-10-31 | — | — | US | disclosed |
| US-20190330223-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2019-10-31 | — | — | US | disclosed |
| EP-3551634-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018108231-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | disclosed |
| US-8765763-B2 | Substituted piperazines as CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| WO-2010139717-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139717-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | WO | disclosed |
| US-7439263-B2 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-21 | — | — | US | disclosed |
| EP-1598350-B1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | SERVIER LAB (FR) | 2007-07-11 | — | — | EP | disclosed |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | US | disclosed |
| EP-1598350-A1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | LES LABORATOIRES SERVIER (FR) | 2005-11-23 | — | — | EP | disclosed |